Epiphany Biosciences Overview

  • Year Founded
  • 1998

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • 2ndary - Private

  • Investors
  • 7

Epiphany Biosciences General Information

Description

Developer of small molecule therapeutics platform designed to treat diseases of herpes virus origin. The company engages in the development of antiviral therapeutics to prevent the spread of the varicella-zoster virus (VZV), Epstein-Barr virus (EBV), and hepatitis C virus (HCV), enabling researchers to prevent or cure the spread of pathogenic viruses.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 1462 42nd Avenue
  • Suite 2800
  • San Francisco, CA 94122
  • United States
+1 (415)
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Other Pharmaceuticals and Biotechnology
Vertical(s)
Corporate Office
  • 1462 42nd Avenue
  • Suite 2800
  • San Francisco, CA 94122
  • United States
+1 (415)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Epiphany Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Secondary Transaction - Private 29-Sep-2021 Completed Generating Revenue
4. Grant 04-Apr-2017 Completed Generating Revenue
3. Later Stage VC (Series A) 14-Mar-2007 Completed Generating Revenue
2. Early Stage VC 01-Dec-1998 Completed Generating Revenue
1. University Spin-Out 01-Jan-1998 Completed Generating Revenue
To view Epiphany Biosciences’s complete valuation and funding history, request access »

Epiphany Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
To view Epiphany Biosciences’s complete cap table history, request access »

Epiphany Biosciences Patents

Epiphany Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20260191871-A1 Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses Pending 28-Nov-2022
WO-2024118480-A1 Use of antiviral agents, composition of matter, combination preparations/agents to treat chronic diseases associated with epstein-barr virus and other human herpes viruses Inactive 28-Nov-2022
WO-2014047562-A2 Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain Inactive 21-Sep-2012
WO-2014047562-A3 Method of treating and/or preventing shingles and method of treating and/or preventing zoster associated pain Inactive 21-Sep-2012
US-20150050241-A1 Method of treating viral infections Inactive 21-Sep-2012 A61K31/522
To view Epiphany Biosciences’s complete patent history, request access »

Epiphany Biosciences Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Angel (individual) Minority
Angel (individual) Minority
CDIB BioScience Venture Management Venture Capital Minority
Global Trust Ventures PE/Buyout Minority
Windsor Bay Capital Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Epiphany Biosciences FAQs

  • When was Epiphany Biosciences founded?

    Epiphany Biosciences was founded in 1998.

  • Where is Epiphany Biosciences headquartered?

    Epiphany Biosciences is headquartered in San Francisco, CA.

  • What industry is Epiphany Biosciences in?

    Epiphany Biosciences’s primary industry is Biotechnology.

  • Is Epiphany Biosciences a private or public company?

    Epiphany Biosciences is a Private company.

  • What is Epiphany Biosciences’s current revenue?

    The current revenue for Epiphany Biosciences is .

  • How much funding has Epiphany Biosciences raised over time?

    Epiphany Biosciences has raised $36.2M.

  • Who are Epiphany Biosciences’s investors?

    , , CDIB BioScience Venture Management, Global Trust Ventures, and Windsor Bay Capital are 5 of 7 investors who have invested in Epiphany Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process